Linked Life Data

16848723

Source:http://linkedlifedata.com/resource/pubmed/id/16848723

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-7-19
pubmed:abstractText
Thalidomide and its immunomodulatory derivatives have provided the most significant advance in the therapy of myeloma since the introduction of high dose chemotherapy followed by stem cell transplantation nearly 20 years ago. The mechanism of action of thalidomide is complex and involves many aspects of malignant plasma cell growth and bone marrow stromal cell microenvironment interaction. Thalidomide was first used because of its anti-angiogenic properties, however it is the immunomodulatory actions that involve increasing host tumour-specific immunosurveillance by both T cell and natural killer cells which may be the most important mode of action.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1568-0096
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
325-31
pubmed:dateRevised
2008-9-9
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
The use of thalidomide in myeloma therapy as an effective anticancer drug.
pubmed:affiliation
Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia. d.sze@pharm.usyd.edu.au
pubmed:publicationType
Journal Article, Review